Abstract: Pancreatic cancer is a highly lethal disease, where the mortality closely matches increasing incidence. Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic type that tends to metastasize early in tumor progression. For metastatic PDAC, gemcitabine had been the mainstay treatment for the past three decades. The treatment landscape has changed since 2010, and current first-line chemotherapy includes triplet drugs like FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and doublet agents like nab-paclitaxel and gemcitabine. Nanoliposomal encapsulated irinotecan (nal-IRI) was developed as a novel formulation to improve drug delivery, effectiveness, and limit toxicities. Nal-IRI, in combination with leucovorin-modulated fluorouracil (5-FU/LV), was found in a large randomized phase III clinical trial (NAPOLI-1) to significantly improve overall survival in patients who progressed on gemcitabine-based therapy. This review will focus on the value of using nal-IRI, toxicities, recent clinical experiences, and tools to improve patient outcomes in this setting.

Keywords: liposomal irinotecan, nal-IRI, pancreatic cancer, pancreatic ductal adenocarcinoma, refractory cancer


Continue Reading

Pancreatic cancer, often referred to pancreatic ductal adenocarcinoma (PDAC), is the fourth most common cause of cancer death in the USA. In 2018, it was estimated that 55,440 cases were diagnosed and 44,330 patients died.1 Total deaths from pancreatic cancer are increasing and are expected to be the second leading cause of cancer death in the USA by 2030.2 This is due to many factors, including limited screening tests, limited efficacy of currently approved chemotherapeutic treatment, and because pancreatic cancer is often diagnosed at late stages, leading to poor outcomes.

There has been a substantial increase in knowledge about underlying mechanisms and pathophysiology of pancreatic cancer. In agreement to its predilection for spreading, a preclinical study using transgenic mice suggested that pancreatic cancer is possibly a systemic disease even at its early stage.3 Studies have implicated alterations in tumor drivers, such as RAS, AKT, WNT, B catenin, and PI3K, as well as loss of function in tumor suppressors, such as P53, P16, Smad4/DPC4 and APC.4–6 Moffitt et al investigated the gene expression in primary and metastatic PDAC tissues by using the source separation technique called nonnegative matrix factorization (NMF). They classified PDAC into two subtypes, basal-like subtype and classical subtype tumors. Patients with basal-like subtype tumors have worse prognosis with an overall median survival of 11 months and 44% 1-year survival compared with 19 months and 70% 1-year survival for patients with classical subtype tumor. However, it was found that basal-like subtype tumors showed better responses to adjuvant therapy hazard ratio (HR) =0.38, compared with HR =0.76 for the classical subtype tumor. They also found that the KRAS G12D mutation was significantly overexpressed in the basal-like subtype while G12V was overexpressed in the classical subtype. Additional mutated genes, such as SMAD4, GATA6, and STK11, were further identified as important in PDAC pathology.7 Ying et al demonstrated how KRASwas critical for PDAC progression, and approximately 93% of PDAC specimens had KRAS mutations.8,9Another study used KRAS2 mutations for the diagnosis of PDAC compared to chronic pancreatitis.10Multiple preclinical and clinical attempts, and extensive research efforts have been made to inhibit KRAS and its effectors such as MEK 1–2, Erk 1–2, or Akt. However, despite the efforts, KRAS remains a difficult molecular target to treat and monitor, and efforts continue to translate research findings with potential into clinical trials.11

Surgery remains the only curative treatment in today’s paradigm, but only about 20% of patients diagnosed with pancreatic cancer are candidates for curative resection.12 Even after resection and adjuvant chemotherapy, most patients eventually relapse, and 5-year survival is still only about 15%–20% even for those who underwent tumor resection.13 Importantly, it has been shown that large volume centers have been associated with improved prognosis and outcomes after curative pancreatic cancer resection, as perioperative mortality and complications are closely associated with the complexity of the surgery itself.14

Overall 5-year survival for pancreatic cancer is about 6% in the USA, and in the metastatic setting, PDAC is almost always fatal.15 Ghosn et al have examined the many dilemmas for oncologists and patients regarding how to approach first-line regimens in PDAC. Clinical efficacy, toxicity, patient preferences, and tumor characteristics should be included in the decision-making process.16 National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) treatment guidelines recommend clinical trials as the preferred options, and FOLFIRINOX (folinic acid, 5-fluorouracil [5-FU], irinotecan, and oxaliplatin) or nab-paclitaxel (nanoparticle albumin-bound-paclitaxel) and gemcitabine combination therapy for patients with good performance status.17,18 Other treatment options include gemcitabine and erlotinib, gemcitabine and capecitabine, or gemcitabine monotherapy for patients with poor performance status. Best supportive care could also be an option for patients with a debilitating status or multiple medical comorbidities based on physician’s discretion.17 FOLFIRINOX, and nab-paclitaxel and gemcitabine combination therapy are the preferred first-line chemotherapeutic regimens for patients with good performance status. However, most patients with PDAC eventually relapse, leaving them with few options for later lines of therapy.

Nanoliposomal irinotecan (nal-IRI) has been developed as a formulation to improve drug delivery and reduce side effects. Combined with fluorouracil and leucovorin (5-FU/LV), nal-IRI has shown significant benefit compared to 5-FU/LV alone in terms of overall survival and progression-free survival (PFS) in patients who progressed on prior gemcitabine-based therapy.19 In this review, we will briefly examine traditional systemic therapy options, and further explore the novel approaches to metastatic pancreatic cancer, including nal-IRI. We will discuss the value of using this drug, associated toxicities, and clinical outcomes.